Ornithine Transcarbamylase Deficiency (OTC) Sequencing and Deletion/Duplication
Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 2 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background Information for Ornithine Transcarbamylase Deficiency (OTC) Sequencing and Deletion/Duplication:
Characteristics: Classic OTC deficiency is a urea cycle disorder characterized by hyperammonemia, cyclical vomiting, seizures, lethargy, coma and neonatal death if not treated. Clinical presentation varies widely in females, and some males can have non-classical forms.
Incidence: Approximately 1 in 20,000.
Penetrance: Variable depending on sex and mutation.
Cause: Pathogenic OTC gene mutations.
Clinical Sensitivity: Approaches 90 percent.
Methodology: Bidirectional sequencing of the entire coding region and intron-exon boundaries of the OTC gene. Multiplex ligation-dependent probe amplification (MLPA) to detect large OTC coding region deletions/duplications.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations and deep intronic mutations will not be detected. The breakpoints of large deletions/duplications will not be determined.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2004897||OTC Deficiency (OTC) Seq,DelDup Specimen||31208-2|
|2004898||OTC Deficiency (OTC) Seq,DelDup Interp||43233-6|
- OTC sequencing and deletion/duplication assay
- Urea Cycle Defect